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Introduction
B-cell lymphoproliferative disease, especially large
cell lymphoma, is a well-recognized complication of
immunosuppression early after organ transplantation,
whereas the incidence of multiple myeloma does not
appear to be increased [1]. We wish to report a patient
who was diagnosed as having multiple myeloma during
intense immunosuppression after renal transplantation.
All abnormalities, however, later disappeared after
reduction of immunosuppression.
Subjects and methods
The patient, a 51-year-old woman, had suffered from chronic
glomerulonephritis since 1958. End-stage renal failure had
been reached in 1976 and maintenance haemodialysis was
begun. A first cadaveric renal transplant was rejected under
conventional immunosuppression with azathioprine and
prednisone within 6 weeks in 1978. Since she developed high
titres of panel-reactive antibodies, she could not be retrans-
planted for several years thereafter.
In October 1990 she finally received a second cadaveric
kidney graft. Immunoelectrophoresis before transplantation
was normal. Because of her history of rejection and lymph-
ocytotoxic antibodies, an intensified immunosuppressive regi-
men was administered, consisting of 5 mg OK.T3 for 14 days,
cyclosporin 400 mg daily from day zero, azathioprine
2 mg/kg and methylprednisolone pulses for 3 days followed
by 0.5 mg/kg of oral prednisone thereafter (Figure 1).
Although the graft functioned well from the first day,
biopsy-proven vascular rejection on day 23 required therapy
with seven daily doses of 5 mg OKT3, and seven pulses of
methylprednisolone. The retreatement was well tolerated
except for diarrhoea and slight pancytopenia. The patient
had to be readmitted on day 40 because of an increase in
serum creatinine, and subfebrile temperature, dyspnoea,
and cough.
Admission serum protein electrophoresis revealed biclonal
gammopathy, IgG kappa and lambda. Bronchoscopy speci-
mens stained positive for Pneumocystis carinii, which
prompted a therapy with co-trimoxazole. She was treated
for suspected rejection with four additional steroid pulses
and 7 days of rabbit anti-thymocyte globulin (ATG
Fresenius) 2 mg/kg body weight. Serum IgG increased from
8.1 g/1 at transplantation to 33.1 g/1 by day 57. Urine
electrophoresis was trace positive for the IgG kappa mono-
clonal component. Bone marrow examination revealed
plasma cell infiltrates of 30% (focally up to over 50%). These
cells were polymorphic with atypical nuclei, some with blastic
nuclear structure (Figure 2). A radiological work-up for
osteolysis or organ infiltration was negative.
A diagnosis of multiple myeloma was made and removal
of the renal transplant was therefore considered. However,
since graft function improved in response to the rejection
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Fig. 1. Course of the patient's disease (top) and administered
immunosuppression (bottom). B.Wt. = body weight.
11993 European Dialysis and Transplant Association-European Renal Association
1394
Fig. 2. Bone marrow smear with dense infiltrate of plasma cells.
treatment, immunosuppression could be reduced (see
Figure 1) at week 13. At day 90 the clonal gammopathy had
disappeared. A repeat bone marrow at that time showed less
than 5% plasma cells. Today, 18 months after transplanta-
tion, her graft functions satisfactorily with a serum creatinine
of 109 umol/1. Immunosuppression is maintained with 300 mg
cyclosporin and 7.5 mg prednisone daily. Serum protein
electrophoresis still shows no sign of clonal gammopathy.
Discussion
In summary, this patient developed clonal gammopa-
thy after intense immunosuppression with OKT3 (total
dose 105 mg) and MP pulses in addition to the baseline
medication with prednisone, azathioprine and
cyclosporin. Bone marrow examination disclosed
polymorphic infiltrates of plasma cells. By commonly
recognized criteria the combination of > 10% plasma
cell infiltrate and clonal gammopathy in serum or urine
allows the diagnosis of multiple myeloma [2]. However,
reduction of immunosuppression was followed by com-
plete disappearance of all abnormalities.
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Multiple myeloma has only rarely been reported
after renal transplantation [3], but clonal gammo-
pathies are frequently encountered in transplant
patients [4]. Their reported incidence ranges between
4 and 68%, depending on the organ transplantated,
the timing of sampling, and the sensitivity of the
methods used to detect clonality [5]. Not unexpectedly
the incidence appears to be greatest after bone marrow
transplantation [6] and may be least after renal trans-
plantation [7]. Clonal gammopathy after transplanta-
tion is often transient, and the quantity of clonal
immunoglobulin is generally small [4]. The cause of
pathological clonal expansion is believed to be
impaired control of B-cell clones by suppressor T cells,
most probably due to immunosuppression [8].
Spontaneous remissions have to our knowledge not
been reported in multiple myeloma. Since there is no
sharp distinction between monoclonal gammopathy
and multiple myeloma, there may be a zone of dia-
gnostic overlap. B-cell lymphomas after organ trans-
plantation are well known and their disappearance
after dose reduction of immunosuppressives has been
reported.
The lesson to be learned from the present case is
that a transient plasma cell dyscrasia may present like
multiple myeloma in the setting of heavy immunosup-
pression after organ transplantation. The alarming
findings suggesting myeloma after OKT3 therapy may
completely resolve simply by reducing immunosuppres-
sion without sacrificing the transplant.
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